MentionFox
Home › Executive changes › NovoCure Ltd
Leadership changes · SEC Form 8-K, Item 5.02

NovoCure Ltd executive changes

Every leadership change NovoCure Ltd reported to the SEC under Item 5.02: who left, who was appointed, to what role and from when, quoted from each filing.

Filings2
Departures named1
Latest filing2026-09-09

NovoCure Ltd filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-09-09. Between them they name 1 person. Each change below is quoted from the filing and linked to it.

Every change, newest first

Filed 2026-09-09 · 8-K

Departing: Timothy Scannell, Director, effective 2026-09-02

(b) Timothy Scannell, a current director of NovoCure Limited (the "Company"), has retired from the Board and his seat was formally vacated pursuant to the Company's Articles of Association effective September 2, 2026.
Filed 2026-04-24 · 8-K/A

Reported

Leonard Employment Agreement In connection with his appointment as Chief Executive Officer, on April 20, 2026, Mr. Leonard entered into a new employment agreement with a subsidiary of the Company (the "Leonard Employment Agreement"), effective January 1, 2026.
Hiring for a seat like this?

Find people with the same kind of experience as the Director at NovoCure Ltd, with the record behind each one.

Find candidates like Director at NovoCure Ltd
Selling to NovoCure Ltd?

New leaders review vendors and budgets in their first months. Get an alert the next time NovoCure Ltd is in the news or changes leadership.

Get an alert when NovoCure Ltd changes leadership

Tools for this story

Each opens in a new tab, filled in for NovoCure Ltd. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/novocure
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2
NovoCure Ltd (NVCR) executive changes: Timothy Scannell departs, Director. MentionFox, 2026-09-27. https://mentionfox.com/executive-changes/novocure